Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype
- PMID: 20714679
Carnitine-acylcarnitine translocase deficiency. Clinical course of three Saudi children with a severe phenotype
Abstract
Carnitine-acylcarnitine translocase (CACT) deficiency (McKusick 212138) is a rare life threatening disorder characterized by hypoketotic hypoglycemia, hyperammonemia, encephalopathy, cardiomyopathy hepatopathy, and myopathy. Here, we present a detailed clinical course of 3 Saudi siblings with a severe phenotype. The third patient was described in more detail. Early medical intervention in the form of 25% dextrose intravenous infusion and carnitine supplement followed by a gradual introduction of a high carbohydrate low fat special formula resulted in a good clinical and biochemical response to the treatment in our patient. However, early nephrocalcinosis, severe hypotonia, and subsequently intravascular cerebral accident could not be prevented. He died at 18 months of age as a result of metabolic decompensation. This suggests that CACT deficiency is still a lethal disorder even with an early and aggressive medical intervention.
Comment in
-
Carnitine-acylcarnitine translocase deficiency. Clinical course of 3 Saudi children with a severe phenotype.Saudi Med J. 2011 Feb;32(2):203; author reply 203. Saudi Med J. 2011. PMID: 21301774 No abstract available.
Similar articles
-
Carnitine-acylcarnitine translocase deficiency, clinical, biochemical and genetic aspects.Mol Aspects Med. 2004 Oct-Dec;25(5-6):521-32. doi: 10.1016/j.mam.2004.06.007. Mol Aspects Med. 2004. PMID: 15363639 Review.
-
Carnitine/acylcarnitine translocase deficiency (neonatal phenotype): successful prenatal and postmortem diagnosis associated with a novel mutation in a single family.Mol Genet Metab. 2001 May;73(1):64-70. doi: 10.1006/mgme.2001.3162. Mol Genet Metab. 2001. PMID: 11350184
-
Molecular and functional analysis of SLC25A20 mutations causing carnitine-acylcarnitine translocase deficiency.Hum Mutat. 2004 Oct;24(4):312-20. doi: 10.1002/humu.20085. Hum Mutat. 2004. PMID: 15365988
-
Carnitine-acylcarnitine translocase deficiency. Clinical course of 3 Saudi children with a severe phenotype.Saudi Med J. 2011 Feb;32(2):203; author reply 203. Saudi Med J. 2011. PMID: 21301774 No abstract available.
-
Carnitine-acylcarnitine translocase deficiency: identification of a novel molecular defect in a Bedouin patient.J Inherit Metab Dis. 2004;27(2):267-73. doi: 10.1023/B:BOLI.0000028780.01670.61. J Inherit Metab Dis. 2004. PMID: 15159657 Review.
Cited by
-
Carnitine-acylcarnitine translocase deficiency: experience with four cases in Spain and review of the literature.JIMD Rep. 2015;20:11-20. doi: 10.1007/8904_2014_382. Epub 2015 Jan 23. JIMD Rep. 2015. PMID: 25614308 Free PMC article.
-
Metabolic interactions between peroxisomes and mitochondria with a special focus on acylcarnitine metabolism.Biochim Biophys Acta Mol Basis Dis. 2020 May 1;1866(5):165720. doi: 10.1016/j.bbadis.2020.165720. Epub 2020 Feb 10. Biochim Biophys Acta Mol Basis Dis. 2020. PMID: 32057943 Free PMC article. Review.
-
Fatty acid oxidation disorders.Ann Transl Med. 2018 Dec;6(24):473. doi: 10.21037/atm.2018.10.57. Ann Transl Med. 2018. PMID: 30740404 Free PMC article. Review.
-
The use of sodium DL-3-Hydroxybutyrate in severe acute neuro-metabolic compromise in patients with inherited ketone body synthetic disorders.Orphanet J Rare Dis. 2020 Feb 18;15(1):53. doi: 10.1186/s13023-020-1316-x. Orphanet J Rare Dis. 2020. PMID: 32070364 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical